BUZZ — Caribou plunges as it explores sale, scraps cancer programs

* Shares of Caribou Biosciences fall 35.9% to 72 cents premarket * Caribou Biosciences said late on Tuesday it was exploring strategic alternatives, including a potential sale, merger or other transaction to maximize shareholder value * Caribou said it planned to discontinue development of its allogeneic CAR-T cell therapy programs, vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma * Caribou said it would cut jobs and reduce costs, with most workforce reductions expected to be completed in Q4 2026 * It had $113.8 million in cash, cash equivalents and marketable securities as of June 30 * As of last close, stock fell ~28% YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;)